Kingdoms collide as bacteria and cells form captivating connections
Studying the pathogen R. parkeri, researchers discovered the first evidence of extensive and stable interkingdom contacts between a pathogen and a eukaryotic organelle.
Studying the pathogen R. parkeri, researchers discovered the first evidence of extensive and stable interkingdom contacts between a pathogen and a eukaryotic organelle.
Using this model, researchers may be able to identify antibody drugs that can target a variety of infectious diseases.
Using high-powered lasers, this new method could help biologists study the body’s immune responses and develop new medicines.
Chronic diseases like diabetes are prevalent, costly, and challenging to treat. A common denominator driving them may be a promising new therapeutic target.
New research reveals what it takes for a protein that is best known for protecting cells against death to take on the opposite role.
Professors Matthew Vander Heiden and Fan Wang, along with five MIT alumni, are honored for their outstanding professional achievement and commitment to service.
By unraveling the genetic pathways that help Toxoplasma gondii persist in human cells, Sebastian Lourido hopes to find new ways to treat toxoplasmosis.
The model could help clinicians assess breast cancer stage and ultimately help in reducing overtreatment.
A new gene-silencing tool shows promise as a future therapy against prion diseases and paves the way for new approaches to treating disease.
Co-hosted by the McGovern Institute, MIT Open Learning, and others, the symposium stressed emerging technologies in advancing understanding of mental health and neurological conditions.
Alnylam Pharmaceuticals, founded by MIT professors and former postdocs, has turned the promise of RNAi research into a new class of powerful therapies.
A microneedle patch that delivers immune-regulating molecules can teach T cells not to attack hair follicles, helping hair to regrow.
In a study of cells from nearly 400 ALS patients, researchers identified genomic regions with chemical modifications linked to disease progression.
Lydia Bourouiba’s research on fluid dynamics influenced new guidance from the World Health Organization that will shape how health agencies respond to respiratory infectious diseases.
Immunai’s founders were researchers at MIT when they launched their company to help predict how patients will respond to new treatments.